Last reviewed · How we verify
Placebo-Cetirizine
Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems.
Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.
At a glance
| Generic name | Placebo-Cetirizine |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | Selective H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Cetirizine competitively binds to H1 histamine receptors on mast cells, basophils, and other immune cells, preventing histamine release and its downstream effects. This reduces symptoms of allergic rhinitis, urticaria, and other IgE-mediated allergic conditions. The drug has minimal anticholinergic and sedating properties due to limited blood-brain barrier penetration.
Approved indications
- Allergic rhinitis
- Chronic urticaria
- Allergic conjunctivitis
Common side effects
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Pharyngitis
Key clinical trials
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial (PHASE3)
- Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study (PHASE3)
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement (PHASE2)
- A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) (PHASE4)
- A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) (PHASE4)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Cetirizine CI brief — competitive landscape report
- Placebo-Cetirizine updates RSS · CI watch RSS
- UCB Pharma portfolio CI